Floatz logo

ANTI-CEACAM1 MONOCLONAL ANTIBODY CM-24

Papillary Thyroid Cancer

Famewave Ltd.monoclonal_antibodyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Papillary Thyroid Cancer cohort.

Asset / SponsorPhaseRating
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Dabrafenib
Cancer Research UK
Phase 2/3B
gsk1120212
Cancer Research UK
Phase 2/3B
Cobimetinib
Cancer Research UK
Phase 2/3B
VEMURAFENIB
Cancer Research UK
Phase 2/3CCC

View all 31 →

Same molecule, other indications

ANTI-CEACAM1 MONOCLONAL ANTIBODY CM-24 is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
melanomaDormant
CC
Indicative ·
47 / 100
View asset →
colorectal adenocarcinomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →